Publication for CEACAM5 and KRT20

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	CEACAM5	CEA cell adhesion molecule 5	1048			[link]
hsa	KRT20	keratin 20	54474

Pubmed ID	Priority	Text
17667927	0.98	CEA, CK20, CK19, MAGE, and MMP-7, have previously been applied to detect micrometastases of gastric cancer (Okami et al, 2000; Yonemura et al, 2001; Kodera et al, 2002; Lin et al, 2002; Matsuda et al, 2004; Arigami et al, 2006; Horibe et al, 2007).
	0.98	CEA or CK20 RT-PCR assay, which were useful for the prediction of peritoneal recurrence were 64.9 and 82.7% or 54.6 and 80.3%, respectively.
	0.97	carcinoembryonic antigen (CEA) and cytokeratin-20 (CK20).
	0.97	CEA mRNA or CK20 mRNA level of the sample was over the cutoff value, the sample was determined to be PCR-positive.
	0.97	CEA or CK20 was positive in 9 and 11, respectively (Figure 1).
	0.97	CEA/GAPDH ratio or CK20/GAPDH ratio for a subsequent analysis in the present study.
	0.97	CEA/GAPDH mRNA ratios and CK20/GAPDH mRNA ratios were plotted according to T stage of TNM classification.
	0.97	CEA and CK20 mRNA levels in the gastric carcinomas.
	0.96	CEA and/or CK20 was an independent prognostic factor for the patients with a curative R0 resection.
	0.95	CEA/GAPDH (Figure 1A) and CK20/GAPDH (Figure 1B) levels were 2.490 x 10-2 and 6.726 x 10-3, respectively.
	0.94	CEA and/or CK-20 expression of the peritoneal lavage fluid and the clinicopathological parameters.
	0.94	CEA and/or CK20 transcripts in the peritoneal lavage specimens has a prognostic relevance in patients who are undergoing a curative resection for T3 and T4 gastric cancer.
	0.93	CEA and CK-20 as diagnostic markers for predicting micrometastasis in patients with gastric carcinoma in this study.
	0.93	CEA/GAPDH mRNA ratios and CK20/GAPDH mRNA ratios level in the peritoneal lavage fluid of the control and T1 samples.
	0.91	CEA and/or CK20), and tumour depth were found to be independent prognostic factors.
	0.88	CEA and/or CK20 examination significantly correlated with the T stage as depth of tumour invasion (P<0.001), peritoneal dissemination (P<0.001), whereas there was no statistically significant association with venous invasion or lymphatic invasion.
	0.88	CEA and/or CK20 transcripts in the peritoneal lavage fluid is thus considered to be useful for predicting the peritoneal recurrence in patients who are undergoing a curative resection for gastric cancer.
	0.87	CEA mRNA and CK20 mRNA expression of the peritoneal lavage fluid of the control samples (n=10), T1 (n=28), T2 (n=23), T3 (n=52), and T4 (n=13), were quantified by RT-PCR.
	0.79	CEA and/or CK20 mRNA levels were 86.4 and 81.5%, respectively.
	0.63	CEA and/or CK20 expression in stages I and II (data not shown).
	0.60	CEA and/or CK20 expression.
	0.57	CEA and/or CK20), T stage, and stage were significantly correlated with patient survival.
	0.53	CEA/GAPDH mRNA ratios and the CK20/GAPDH mRNA ratios according to the depth of the tumour invasion.
31576171	0.98	CEA as a marker (five articles) and several studies also introduced both CK20 and CEA as prognostic markers.
	0.96	CK20 and/or CEA were accompanied by markers such as CK19, GCC, Prominin 1 (CD133), EPCAM, survivin, ProtM, mucin 1 (MUC 1), and mucin 2 (MUC 2), and telomerase reverse transcriptase (hTERT).
	0.88	CK20, CA19-9, and CEA, which is used in clinics routinely for CRC detection, also has been introduced as a marker of CTC in CRC.
17031402	0.97	carcinoembryonic antigen (CEA), cytokeratins (CK20 and CK7), and epithelial membrane antigen (EMA) were primarily determined as these reflect the origin of disease.
	0.96	carcinoembryonic antigen (CEA), cytokeratins (CK20 and CK7), epithelial membrane antigen), mucin production (MUC-2, interleukin-9 (IL-9), IL-9 receptor (IL-9Ralpha)), and cell adhesion (N- and E-cadherin, vimentin) in PMP tissue (n=26) compared with expressions in normal colonic mucosa (n=19) and colorectal adenocarcinoma (n=26).
	0.96	CEA and cytokeratins were similar for PMP as those in colorectal adenocarcinomas with the exception that the CK20-/CK7- pattern was rare in PMP (Fisher's exact test: P=0.001).
	0.96	CEA positive, and all but one was CK20 positive.
	0.94	CEA and CK20, with absent CK7, was universal in well-orientated normal colonic mucosa.
19300524	0.97	CEA, CK8/18, and CK20.
	0.95	CEA (see Figures 3(a) and 3(b)) and CK8/18 (see Figures 3(c) and 3(d)) but did not show expression of CK20 (see Figures 3(e) and 3(f)).
	0.94	CEA, (c), (d) cytokeratin 8/18, and (e), (f) cytokeratin 20.
	0.91	CEA, (c), (d) cytokeratin 8/18, and (e), (f) cytokeratin 20.
	0.80	CEA, (c), (d) cytokeratin 8/18, and (e), (f) cytokeratin 20.
16100458	0.97	CK20, CEA, CA125, and her-2/neu, for distinghuising between these two groups of lesions.
	0.95	CEA and other known markers, such as CK7 and CK20, is necessary to distinguish primary and metastatic mucinous carcinomas.
	0.84	CK20, carcinoembryonic antigen (CEA), human alveolar macrophage-56 (HAM-56), mucin marker (MUC)2, and MUC5AC, are of limited sensitivity and specificity, even though in many settings, they allow the site of origin of a metastatic lesion to be identified.
26947877	0.96	CEA mRNA and CK20 mRNA before HIPEC versus after HIPEC were 4.08 +- 1.34 versus 3.22 +- 0.62 (P = .573) and 0.47 +- 0.09 versus 0.46 +- 0.06 (P = .937), respectively (Figure 3).
	0.96	CEA, CK20, CK19, and MMP for RT-PCR assay could greatly improve both the sensitivity and the specificity of detecting IFCCs and make it a reliable way for clinical use.
	0.92	CEA mRNA and CK20 mRNA positive rate became 22.0% (P = .000), 86.0% (P = .012), and 96.0% (P = .495) after HIPEC, respectively.
	0.91	CEA mRNA and CK20 mRNA after HIPEC.
	0.91	CEA mRNA, and CK20 mRNA positive rates achieved by these methods were all 100%, far more than the other studies had reported, because the patients included in this study were all with visible peritoneal recurrence (median PCI = 22, range = 2-39).
	0.86	CEA mRNA (P = .000), and 17 (34.0%) patients had a decline in CK20 mRNA (P = .000).
	0.78	CEA mRNA and CK20 mRNA positive rates, the relative quantity analysis shows that the relative expression of CEA mRNA decreased in 18 (36.0%) patients (P = .000) and the relative expression of CK20 mRNA decreased in 17 (34.0%) (P = .000).
	0.71	carcinoembryonic antigen (CEA) mRNA, cytokeratin-20 (CK20) mRNA, and serum tumor makers to assess the effect of HIPEC to eradicate IFCCs and the explore feasibility of cytological cure for PC.
	0.68	CEA, CK20, and GAPDH show clear bands at corresponding sites, and all negative controls do not show any bands (Figure 2).
	0.57	CEA mRNA (P = .000) and 17 (34.0%) patients had a decline in CK20 mRNA (P = .000), including 13 (26.0%) patients who had declines in both CEA mRNA and CK20 mRNA.
17603904	0.96	CEA, CK20 and CK7 conform well to previous observations in PMP, and findings within each of the two models were consistent throughout the examined passages.
	0.93	CEA and CK20 (panels A and B, respectively) was observed in primary tumors, main surgical specimens and in all specimens harvested from the first six animal passages, here illustrated by sections from PMP-1 passage 1.
	0.91	CEA and CK20, were highly expressed in both primary tumors, main surgical specimens and in all specimens harvested from the first six animal passages, with membranous and cytoplasmic staining observed in 100% of tumor cells in all but one section.
22148057	0.96	Carcinoembryonic antigen, (B) Cytokeratin 7, (C) CK20, (D) Gross cystic disease fluid protein (magnification, x100).
	0.55	carcinoembryonic antigen, Cam 5.2, epithelial membrane antigen, cytokeratin (CK) 7, and pancytokeratin (AE1/AE3) in both areas, but negative CK20 staining, supporting the overall diagnosis of primary acantholytic anaplastic EMPD.
24040391	0.96	CEA and Ki67 (Figure 6C) but negative for cytokeratin-20 and CD56 (data not shown).
	0.91	CK20-/CEA+/Ki67+/CD56- immunodetection.
20890370	0.95	CK20, survivin, and CEA levels were all independently higher by qRT-PCR in CRC patients versus normal controls.
	0.90	CK20, CK19, CEA, and guanylyl cyclase G (CGG) were shown to identify cancer patients versus healthy patients.
	0.60	CK20 (P=0.011), or CEA (P<0.001) mRNA levels.
24273555	0.95	CEA or CK-20 expression was detected in the remaining 10 patients, who were thus MM negative.
	0.80	carcinoembryonic antigen (CEA) and cytokeratin 20 (CK-20) detection, a two-by-two contingency table was constructed (Table 2).
	0.74	carcinoembryonic antigen (CEA) and cytokeratin 20 (CK-20) expression, as markers for MM involvement.
25364445	0.95	carcinoembryonic antigen; (D) CK5/6-negative expression; (E and F) the positive expression of CK7 (weak) and CK20 (strong); (G) vimentin-negative expression; (H) the diffusely-positive nuclear staining of Ki67; and (I) p53-negative expression.
	0.89	carcinoembryonic antigen, cytokeratin (CK)-7 and CK20, but negative expression for CK5/6 and vimentin.
26685087	0.95	CEA, CA19.9, CA125 usually positive; CK20, CDX2 positive or negative) is characteristic of that expected with a primary pancreatic or biliary adenocarcinoma and highlights that markers commonly used when dealing with a mucinous adenocarcinoma of unknown primary may not distinguish a cervical gastric-type adenocarcinoma from one of pancreaticobiliary origin. .
	0.55	CEA (25/31 - 12 diffuse, 13 focal), CAIX (20/24 - 8 diffuse, 12 focal), PAX8 (32/47 - 20 diffuse, 12 focal), CA125 (36/45 - 5 diffuse, 31 focal), CA19.9 (11/11 - 8 diffuse, 3 focal), HNF1beta (13/14 - 12 diffuse, 1 focal), CDX2 (24/47 - 4 diffuse, 20 focal), CK20 (23/47 - 6 diffuse, 17 focal) and p16 (18/47 - 4 diffuse, 14 focal).
26390158	0.95	CK-20 mRNA and CEA mRNA.
26607425	0.95	CEA negativity (that is usually positive in tumors of the gastrointestinal tract and pancreas) and inconstant positivity for keratin 20.
30621018	0.95	CEA CAR T), anti-prostate specific membrane antigen designer CAR T (PSMA designer CAR T), mRNA CAR T cells directed against c-Met (mRNA c-Met-CAR T), CAR T cells targeting tumor-associated glycoprotein-72 (CART72), CAR-B-cell maturation antigenT (CAR-BCMAT), 19-28z-Toll-like receptor 2 CAR T (1928zT2 CAR T), CD19 CAR T, CD30-targeting CAR T (CART-30), CD22-targeted CAR T (CD22-CAR T), CD20-CAR-modified T (anti-CD20 CART), CD19-targeted 19-28z CAR T (19-28z CAR T), CAR T Cell Against the LeY Antigen (LeY CAR T).
22148056	0.94	CK20, CK7, and diastase-resistant PAS were stained positively in Pagetoid cells, but CEA was stained with faint.
	0.71	CK20, CEA, and MUC 5-AC, and the underlying tumor was not detected by PET-CT.
29504983	0.94	CEA = carcinoembryonic antigen, CK = cytokeratin, CK20 = cytokeratin20, CK7 = cytokeratin7, EMA = epithelial membrane antigen, PAS = periodic acid-Schiff, SMA = smooth muscle actin, SPA = surfactant apoprotein A, TTF-1 = thyroid transcription factor 1.
	0.93	CEA; and consistently negative for TTF-1, SPA, Napsin A, ALK (D5F3), CDX2, CK20, p53, vimentin, and synaptophysin.
32049988	0.94	carcinoembryonic antigen cell adhesion molecule 5 (CEACAM5), kallikrein related peptidase 6 (KLK6), cytokeratin 20 (CK20) and guanylate cyclase 2C (GUCY2C).
27626026	0.93	CEA, x40), (E) positive in adenocarcinomatous component (CK20, x100), (F) negative in tumor cells (CDX2, x40), and (G) focal mucin deposits in tumor cells (D-PAS, x100).
23806209	0.90	carcinoembryonic antigen (CEA, evaluated in 8 of 20 studies, 40%) and cytokeratin-19 (CK-19, evaluated in 8 of 20 studies, 40%) followed by cytokeratin-20 (CK-20, evaluated in 5 of 20 studies, 25%), other markers were EpCAM (10%), hTERT (10%), MUC1 (10%), c-Met (5%), MAGE-1 (5%), Survivin (5%), VEGF (5%), MAGE-3 (5%), GFP (5%).
	0.57	CK-20, and 8 about CEA.
22148025	0.90	CEA, AE1/3, and GCDFP-15 but negative for Melan-A, S-100, and CK20.
29147109	0.88	CEA, cytokeratin 20, and epidermal growth factor receptor (EGFR) on RNA obtained from peripheral blood.
25663934	0.84	CEA, glial fibrillary acidic protein (GFAP), smooth muscle actin (SMA), cluster of differentiation 56 (CD56), thyroid transcription factor-1 (TTF-1), p63, chromogranin A (CgA), synaptophysin (Syn), cytokeratin (CK)20), CK7, leukocyte common antigen (LCA), caudal-type homeobox 2 (CDX-2), neuron-specific enolase (NSE) and CK5/6 were chosen in different combinational panels to confirm the diagnosis of primary ACCL according to the respective condition of the patient.
28775789	0.84	CD20, CD22, ROR1, CD138, BCMA, CD70, LeY, and also including solid malignancies TAA, such as GPC3, HER2, GD2, EGFR variant III (EGFR vIII), EGFR, CEA, PSMA, FRalpha, EPCAM, MUC1, ROR1, MUCI16eto, VEGFR2, CD171, PSCA and EphA2, etc (Figure 1B).
28877221	0.83	cytokeratin 20 and carcinoembryonic antigen.
	0.71	cytokeratin 20 or CEA, also demonstrated variation in expression for individual spheroids.
23725376	0.83	CK20 (6/9), CEA (6/9), Leu M1 (4/5), B-HCG (1/2), CDX-2 (3/4), Muc2 (1/2), Muc5 (2/2), CD5 (8/12), P63 (1/2), CA-19-9 (3/3), CAM5.2 (2/2), CK5,6 (1/2), P53 (2/2), Her2 (1/2).
31340478	0.83	CK20-, CEA-, CA125+) with or without histologically recognizable endometriotic foci in close proximity; (b) exclusion of origin from other primary sites.
31921680	0.81	CK20, CEA, hTerT, c-MET, MUC1, VEGFR-1, Survivin, uPAR, B7-H3, and STCs) and CRC-CTCs (including CK19, CK20, CEA, PLS3, CD133, hTerT, EphB4, LAMgamma2, and MAT) detection.
28272347	0.74	cytokeratin-20 (CK20) in blood mononuclear cells and CEA/CK20/CD133 in peripheral blood using RT-PCR to identify CTCs in rectal cancer.
26346068	0.50	CEA, and MUC, there was no staining with CK20; immunohistochemical staining pattern of the biopsy taken from the bladder was the same as that taken from the stomach and this staining pattern was consistent with primary gastric adenocarcinoma.